Patient perspectives on treatment-related toxicities and therapeutic drug monitoring with tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer
Background: Tyrosine kinase inhibitors (TKIs) have significantly improved treatment-related outcomes of patients with oncogene-driven non-small-cell lung cancer (NSCLC). TKIs are usually well tolerated and used for a prolonged time, although experienced toxicity varies between patients. It is unclea...
Saved in:
| Main Authors: | Judith Gulikers, Jeroen Bruinsma, Janna Schoenmaekers, Safiye Dursun, Vivianne Tjan-Heijnen, Robin van Geel, Sander Croes, Lizza Hendriks |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-12-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241303403 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anti-angiogenic tyrosine kinase inhibitors and the pathophysiology of their toxic effects: revisiting the treatment of anemia in metastatic cancers
by: Tai Van Nguyen, et al.
Published: (2025-04-01) -
Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series
by: Marilda Mormando, et al.
Published: (2024-12-01) -
Cardiovascular Toxicity of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia
by: IL Davydkin, et al.
Published: (2018-10-01) -
Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression
by: Lucia Vráblová, et al.
Published: (2024-12-01) -
Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase Inhibition
by: Antónia Kurillová, et al.
Published: (2025-06-01)